Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CRISBullishResearch Analysisnews

High materiality8/10

Analyst raises CRIS PT to $43 on TakeAim CLL and timeline shifts

Jul 24, 2026, 2:33 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive analyst uplift and near-term CLL/PCNSL readout catalysts could drive sentiment and a multiple- expansion, especially if data align with expectations; historical peers show such updates can yield 5–15% intraday moves and valuation re-ratings.

AI summary

What happened, with direct paths to the underlying reporting

HC Wainwright raises CRIS's price target to $43 on TakeAim CLL progress and potential CLL, PCNSL, and NHL opportunities. Key timelines shift with PCNSL to 2029 and AML/MDS to 2032; enrollment targeted by 2027 and potential accelerated approvals, supported by improving DoR in BTKi-experienced patients. The readouts could be near-term catalysts for upside if data meet expectations.

HC Wainwright raises CRIS price target to $43; reiterates Buy.
TakeAim CLL enrollment ahead; consented patients at 10; year-end guide 5–10.
Emavusertib in CLL: 10% probability; $500M peak sales; 2032 launch.
PCNSL launch pushed to 2029; enrollment by 2027; accelerated filing planned.
AML/MDS launch moved to 2032; funding required.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Analyst raises CRIS PT to $43 on TakeAim CLL and timeline shifts

Curis updates boost PCNSL data and CLL enrollment, signaling regulatory optionality